Design, synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-c]quinazoline derivatives as novel phosphatidylinositol 3-kinase and histone deacetylase dual inhibitors
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Design, synthesis and biological evaluation of 2,3-dihydroimidazo[1,2-c]quinazoline derivatives as novel phosphatidylinositol 3-kinase and histone deacetylase dual inhibitors
Authors
Keywords
-
Journal
RSC Advances
Volume 7, Issue 82, Pages 52180-52186
Publisher
Royal Society of Chemistry (RSC)
Online
2017-11-10
DOI
10.1039/c7ra08835c
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)
- (2016) William J. Scott et al. ChemMedChem
- 6-Aryl substituted 4-(4-cyanomethyl) phenylamino quinazolines as a new class of isoform-selective PI3K-alpha inhibitors
- (2016) Rammohan R. Yadav et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase
- (2016) Chung-Pu Wu et al. MOLECULAR PHARMACEUTICS
- HDACI regulates the PI3K/Akt signaling pathway to reverse MCF-7/PTX resistance by inhibiting SET
- (2016) Weipeng Zhang et al. RSC Advances
- Structural insight into inhibition of human Class II PI3K isoforms: homology modeling, binding site characterization, docking and molecular dynamics studies
- (2016) Vikash Kumar et al. RSC Advances
- Design, synthesis and biological evaluation of 2-amino-N-(2-aminophenyl)thiazole-5-carboxamide derivatives as novel Bcr-Abl and histone deacetylase dual inhibitors
- (2016) Xin Chen et al. RSC Advances
- Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors
- (2015) Ken Saijo et al. CANCER SCIENCE
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- EGFR-TKI Resistance Due to BIM Polymorphism Can Be Circumvented in Combination with HDAC Inhibition
- (2013) T. Nakagawa et al. CANCER RESEARCH
- Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS
- (2013) Takashi Yoshioka et al. GYNECOLOGIC ONCOLOGY
- Targeting PI3K in Cancer: Any Good News?
- (2013) Miriam Martini et al. Frontiers in Oncology
- Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors
- (2012) Yong Zhu et al. ARCHIVES OF PHARMACAL RESEARCH
- Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
- (2010) Jiahuai Tan et al. Journal of Hematology & Oncology
- Histone Deacetylase Inhibitors in Cancer Therapy
- (2009) Andrew A. Lane et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
- (2009) M. L. Sos et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Drug discovery approaches targeting the PI3K/Akt pathway in cancer
- (2008) C Garcia-Echeverria et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now